Immunome (IMNM) Revenue (2023 - 2025)

Immunome's Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q2 2025.

• Quarterly Revenue rose 69.84% year-over-year to $4.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 63.29% YoY) and the FY2025 annual result came in at $6.9 million, down 23.23% from the prior year.
• Revenue was $4.0 million for Q2 2025 at Immunome, up from $2.9 million in the prior quarter.
• Across five years, Revenue topped out at $4.3 million in Q2 2023 and bottomed at $1.0 million in Q1 2024.
• A 3-year average of $3.0 million and a median of $2.9 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue plunged 56.47% — and 2025, when it soared 184.35%.
• Immunome's Revenue stood at $3.8 million in 2023, then declined by 28.44% to $2.7 million in 2024, then jumped by 46.64% to $4.0 million in 2025.
• Business Quant data shows IMNM's Revenue at $4.0 million in Q2 2025, $2.9 million in Q1 2025, and $2.7 million in Q4 2024.